EP1981514A2 - Biomimetic hydroxyapatite synthesis - Google Patents

Biomimetic hydroxyapatite synthesis

Info

Publication number
EP1981514A2
EP1981514A2 EP07718197A EP07718197A EP1981514A2 EP 1981514 A2 EP1981514 A2 EP 1981514A2 EP 07718197 A EP07718197 A EP 07718197A EP 07718197 A EP07718197 A EP 07718197A EP 1981514 A2 EP1981514 A2 EP 1981514A2
Authority
EP
European Patent Office
Prior art keywords
phosphate
calcium
particles
hydroxyapatite
ion source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07718197A
Other languages
German (de)
French (fr)
Inventor
Richard E. Riman
Christina Sever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of EP1981514A2 publication Critical patent/EP1981514A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite

Definitions

  • HAp Hydroxyapatite
  • chemical formula Ca 10 (PO 4 )6(OH) 2 has attracted the attention of researchers over the past thirty years as an implant material because of its excellent biocompatibility and bioactivity.
  • HAp has been extensively used in medicine for implant fabrication. It is commonly the material of choice for the fabrication of dense and porous bioceramics. Its general uses include biocompatible phase-reinforcement in composites, coatings on metal implants and granular fill for direct incorporation into human tissue. It has also been extensively investigated for non-medical applications such as a packing material/support for column chromatography, gas sensors and catalysts, as a host material for lasers, and as a plant growth substrate.
  • Previously explored methods of hydroxyapatite synthesis for particles include plasma spraying, hydrothermal synthesis, freeze drying, sol-gel, phase transformation, mechanochemical synthesis, chemical precipitation, and precipitation in simulated body fluid (SBF). AU of these methods produce products witn varying levels oi purity, size, crystallinity, and yield.
  • Plasma spraying, hydrothermal synthesis, sol-gel, phase transformation, mechanochemical synthesis, and chemical precipitation require elevated temperatures and/or extreme pH values in the fabrication of hydroxyapatite.
  • a calcium ion source which includes calcium acetate
  • a phosphate ion source an amount of phosphate ion source
  • One embodiment includes a stable colloidal suspension of nanoscale hydroxyapatite particles suspended in a biocompatible ionic solution prepared by the method of the present invention, wherein the ionic solution includes physiological concentrations of phosphate and acetate anions and sodium or potassium cations.
  • powdered hydroxyapatite particles having a BET surface area between about 200 and about 3000 m 2 /g and a particle size between about lnm and about 9nm.
  • a stable colloidal suspension of the hydroxyapatite particles suspended in a biocompatible ionic solution is provided.
  • the kit includes (a) an amount of a calcium ion source, which includes calcium acetate, and (b) an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscaie hydroxyapatite particles when combined under ambient conditions.
  • FIGS, la-d are transmission electron microscopy (TEM) images of particles prepared according to the method of Example 2;
  • FIGS. 2a-b are TEM images of particles prepared according to the method of Example 3;
  • FIG. 2c is a TEM image of particles prepared according to the method of
  • Example 3 at a higher magnification than the images of FIGS. 2a-b;
  • FIG. 2d is a TEM image of particles prepared according to the method of Example 3 showing a particle size distribution of +/- lOnm;
  • FIG. 2e is a high resolution transmission electron microscopy (HRTEM) image of particles prepared according to the method of Example 3 ;
  • FIG. 3a is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1;
  • FIG. 3b is an XRD spectrum corresponding to HAp particles prepared according to the method of Example 2
  • FIG. 3c is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1, wherein the reactant concentrations were halved
  • FIG. 3d is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1, wherein the particles were heat treated at 900 0 C for 2 hours.
  • the present invention is related to methods for preparing nanoscale HAp particles and the HAp particles prepared therewith. Kits for use in preparing the particles and colloids containing the particles are also presented. Hydroxyapatite has reported uses for biomedical, chromatographic, and piezoelectric applications and has been synthesized by various techniques. However, reaction conditions for the preparation of HAp such as high temperatures, high pressures and extreme pH values, as well as low yield, vigorous washing requirements, and long reaction times limit biological applications. The methods of the present invention permit the formation under mild reaction conditions of HAp under conditions suitable for the above uses, especially biological use.
  • the method involves combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale HAp particles and the amounts are combined under essentially ambient conditions to produce the HAp particles.
  • Suitable phosphate ion sources include, but are not limited to, one or more of potassium or sodium orthophosphate; orthophosphoric acid; Group I phosphates, preferably monobasic, dibasic, or tribasic potassium or sodium phosphate; magnesium phosphate; ammonium phosphate; and the like. Potassium or sodium orthophosphate is preferred.
  • the calcium ion source may include one or more of calcium hydroxide, calcium oxalate, calcium acetate, calcium nitrate, calcium phosphate, calcium carbonate, calcium fluoride, and calcium chloride. Calcium acetate alone is preferred.
  • the calcium ion source, the phosphate ion source, or both are in solution prior to combining the sources.
  • the solution contains one or more of water, buffer, solvent, simulated body fluid, or fortified cell medium with or without serum.
  • Suitable buffers include, but are not limited to, N-(2-hydroxyethyl)-piperazine-N'-2- ethanesulfonic acid (HEPES), 2-(bis(2-hydroxyethyl)amino)-2-(hydroxymethyl)propane- 1,3-diol (BIS-TRIS), 3-(N-Mor ⁇ holino)-propanesulfonic acid (MOPS), N-(2- Acetamido)-2-aminoethanesulfonic acid (ACES), N-(2-Acetamido)iminodiacetic Acid (ADA), N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic Acid (BES), 3-[N,N-bis(2-
  • Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid TAPSO
  • N- Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid TES
  • a preferred buffer is acetic acid.
  • An optional step includes agitating the combination until HAp is formed.
  • agitate refers to mechanical movement, for example, vibrating, vortexing, swirling, shaking, ultrasonicating, stirring, or the like that causes mixing.
  • Mechanical movements include movements performed by hand.
  • This thixotropic material exhibits shear thinning after further intense agitation and returns to a milky solution.
  • this solution is allowed to age for a period between 2 minutes and 10 days.
  • additional agitation may or may not be applied to continue mixing. The aging time allows Ostwald ripening of the particles, therefore, the particles aged longer exhibit a larger particle size.
  • a preferred temperature range is between -1O 0 C and 45°C.
  • HAp particles are typically produced within 1 minute to an hour. Combining the sources while heating will speed up the rate of reaction to more quickly produce HAp, while combining the ion sources while cooling will decrease the rate at which HAp particles form.
  • a pH swing may occur, which is varied with the calcium to phosphate stoichiometry.
  • a preferred embodiment in which the calcium to phosphate ratio is about 1.67, exhibits a pH swing of 12 down to 7 over the time of a 4 hour reaction.
  • the pH of the gel phase is 12; just after the shear thinning and return to solution, the pH is 10; after 3 hours of reaction, the pH is 8; and after 4 hours of reaction, the pH returns to neutral.
  • the time to neutral also depends on the employment or omission of agitation throughout the reaction that may enhance kinetics and diffusion of the ions in the formation of hydroxyapatite.
  • a buffer as the reaction medium moderates the pH change, which affects the product formed. Hydroxyapatite is formed, but secondary phases of calcium phosphate and calcium carbonate may be additionally formed, but can be remedied through process variations, for example, bubbling with nitrogen, addition of chelating agents, or use of additional pH adjustments or buffers.
  • Another optional step includes adding one or more dopant ions suitable for substitution into the HAp lattice.
  • dopant ions suitable for substitution into the HAp lattice.
  • ions include, but are not limited to, magnesium, fluorine, chlorine, potassium, iron, carbonate, sodium, and the like.
  • the HAp particles of the present invention can also be doped with ions of one or more rare earth elements.
  • a washing step can be performed. This step includes, for example, filtration, centrifuging, and/or liquid replacement. Centrifuging or liquid replacement are preferred. Minimal washing cycles are needed because of the nontoxic nature of the ions left in solution.
  • the citrate wash disclosed in U.S. Patent No. 6,921,544, the contents of which are incorporated herein by reference in their entirety is used to remove at least a portion of an amorphous phase if the amorphous phase is considered an undesired impurity.
  • drying techniques are readily determinable by those of skill in the art.
  • Preferred drying techniques include evaporative and sublimation-based drying methods, for example, oven drying and freeze drying.
  • the methods according to the present invention can take place in any suitable reaction system.
  • An exemplary system includes a flow reactor for continuous production of hydroxyapatite.
  • the HAp particles have a BET surface area between about 200 and about 3000 m 2 /g and a particle size between about 1 nm and about 9 nm. In one embodiment, the particles have a dispersed particle size between about 1 and about 9 nm.
  • the term "dispersed” is defined herein in the context of colloidal chemistry where the particles maintain an inter-particle spacing such that no physical contact is made between the particles.
  • the term “aggregated” is defined herein as adjacent particles having no inter-particle spacing and making contact with the nearest neighboring particles.
  • the particles are aggregated and have an aggregated particle size equal to or greater than about 2 nm, preferably between about 2nm and about 5 mm.
  • the composition of the powdered HAp particles is stoichiometric or non- stoichiometric with respect to calcium and phosphate.
  • the XRD diffraction pattern of FIG. 3d represents the results of a standard test for stoichiometry.
  • FIG. 3d shows the presence of peaks corresponding to tricalcium phosphate (TCP) after the sample was heat treated at 900 0 C for 2 hours.
  • TCP tricalcium phosphate
  • the presence of TCP indicates a non- stoichiometric composition and/or an amorphous phase.
  • at least a portion of the composition includes an amorphous phase.
  • the ratio of calcium to phosphate in the HAp particles is between 1.25 and 2.5.
  • the HAp particles exhibit a spherical or non-spherical morphology.
  • the term "spherical” is used herein to mean equiaxed particles having either a primary or secondary particle structure. Given that hydroxyapatite has no toxicity and its components are low cost, such a technology presents great promise for a range of applications.
  • HAp particles having the size distribution of the present invention are effective in drug delivery because they are more capable of penetrating the cellular wall and carry a much higher surface area for adsorption of drug molecules.
  • the range also allows the particles to be used intravenously as a drug therapy or for transdermal drug delivery.
  • the size range is also important in biomaterial applications because it is close to what is seen naturally in the body. Being smaller, it will also be more readily processable by cells and tissues for regeneration and resorption.
  • Devices based on hydroxyapatite are typically in the form of polycrystalline ceramics, polymer-ceramic composites, or films on a metallic surface such as titanium.
  • the powders produced in this invention can be used in conventional processes to make all three forms of materials, using conventional methods such as solid state sintering for polycrystalline ceramics, polymer-melt processing for polymer-ceramic composites and plasma spraying for hydroxyapatite-coated titanium metal.
  • the particles of this invention can be grown directly onto the metal surfaces without the need for any high temperature processing.
  • the hydroxy apatite of the present invention is also useful in the preparation of compounds for use as granular fill for direct incorporation into the hard tissues of humans or other animals, and as bone implantable materials.
  • the present invention thus includes granular fill compounds, bone implant materials, tooth filling compounds, bone cements and dentifrices containing the hydroxyapatite of the present invention.
  • the products are formulated and prepared by substituting the hydroxyapatite of the present invention for hydroxyapatite in conventional hydroxyapatite-based products.
  • the compounds may be prepared from metallic and polymeric hydroxyapatite composites. Suitable polymers include polysaccharides, poly(alkylene oxides), polyarylates, for example those disclosed in U.S. Patent No.
  • 5,216,115 block co-polymers of poly(alkylene oxides) with polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 5,658,995, polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 5,670,602, free acid polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 6,120,491, polyamide carbonates and polyester amides of hydroxy acids, for example those disclosed in U.S. Patent No. 6,284,862, polymers of L-tyrosine derived diphenol compounds, including polythiocarbonates and polyethers, for example those disclosed in U.S. Patent No.
  • RE37,795 strictly alternating poly(alkylene oxide) ethers, for example those disclosed in U.S. Patent No. 6,602,497, polymers listed on the United States FDA "EAFUS" list, including polyacrylamide, polyacrylamide resin, modified poly(acrylic acid-co- hypophosphite), sodium salt polyacrylic acid, sodium salt poly(alkyl(C 16-22) acrylate), polydextrose, poly(divmylbenzene-co-ethylstyrene), poly(divinylbenzene-co- trimethyl(vinylbenzyl)ammonium chloride), polyethylene (m.w.
  • polyethylene glycol polyethylene glycol (400) dioleate, polyethylene (oxidized), polyethyleneimine reaction product with 1,2-dichloroethane, polyglycerol esters of fatty acids, polyglyceryl phthalate ester of coconut oil fatty acids, polyisobutylene (min. m.w. 37,000), polylimonene, polymaleic acid, polymaleic acid, sodium salt, poly(maleic anhydride), sodium salt, polyoxyethylene dioleate, polyoxyethylene (600) dioleate, polyoxyethylene (600) mono-rici noleate, polyoxyethylene 40 monostearate, polypropylene glycol (m.w.
  • polysorbate 20 polysorbate 60, polysorbate 65, polysorbate 80, polystyrene, cross-linked, chloromethylated, then aminated with trimethylamine, dimethylamine, diethylenetriamine, or triethanolamine, polyvinyl acetate, polyvinyl alcohol, polyvinyl polypyrrolidone, and polyvinylpyrrolidone, and polymers listed in U.S. Patent No. 7,112,417, the disclosures of all of which are incorporated herein by reference in their entirety.
  • kits for use in preparing nanoscale HAp particles of the present invention includes (a) an amount of a calcium ion source comprising calcium acetate and (b) an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale HAp particles when combined under ambient conditions.
  • the kit can be used to prepare HAp particles prior to the introduction of the particles into a patient.
  • the kit can be used to combine components (a) and (b) in a patient in need thereof for the preparation, and subsequent deposit, of HAp particles in vivo.
  • the two ion sources are provided in separate containers. Other components may be present depending upon the intended therapeutic use.
  • Yet another aspect of the present invention includes a stable colloidal suspension with nanoscale HAp particles suspended in a biocompatible ionic solution prepared according to the methods of the present invention, wherein the ionic solution includes physiological concentrations of phosphate and acetate anions and sodium or potassium cations. Also presented is a stable colloidal suspension with the HAp particles of the present invention suspended in a biocompatible ionic solution.
  • the ionic solution includes the mother liquor from which the hydroxyapatite particles were produced.
  • the mother liquor can be formulated to produce an ionic buffer upon HAp formation.
  • the mother liquor could form a phosphate buffered saline (PBS) solution upon formation of HAp.
  • the ionic solution includes a solution prepared independently of the hydroxyapatite particles, for example, one of the aforementioned buffers.
  • Example 1 Room temperature crystallization of hydroxyapatite in water.
  • Calcium acetate hydrate (99% Acros Organics, Belgium, CAS # 114460-21-8) and potassium orthophosphate hydrate (Acros Organics, Belgium, CAS# 27176-10-9) were used as reactants for the synthesis of hydroxyapatite.
  • a 1.0 molal calcium acetate hydrate solution was made using distilled, deionized water.
  • a 0.6 molal solution of potassium orthophosphate hydrate was made using distilled, deionized water.
  • Equal volumes of each were then measured out for the reaction to create a calcium to phosphate ratio of 1.67 (final concentrations of ions if they were to remain in solution would be 0.5m/0.3m).
  • a 100 mL reaction required 5OmL of the calcium solution to be measured and poured into a beaker and 5OmL of the phosphate solution to be added. Agitation via vortexing was then performed until and through the gelation stage. Once the gel returned to solution, the slurry was then allowed to age for 2 minutes. The concentrate was then dried in an oven at 7O 0 C for 24 hours and desiccated until use or immediately atomized onto a Transmission Electron Microscopy (TEM) grid for characterization.
  • TEM Transmission Electron Microscopy
  • FIG. 3a is an XRD diffraction pattern corresponding the HAp particles prepared according to this method, which were washed followed by drying in a 7O 0 C oven.
  • the broadness of the peaks in FIG. 3a indicates nanoscale particles.
  • the peaks match the standard reference peaks for hydroxyapatite.
  • Helium pycnometry confirms an average particulate density of 2.4 g/cm 3 .
  • FIG. 3c is an XRD diffraction pattern corresponding to HAp particles prepared according to this method, wherein the reactant concentrations were halved.
  • FIG. 3c also confirms the presence of HAp particles.
  • Example 2 Room temperature crystallization of hydroxyapatite in water. Hydroxyapatite was prepared according to the method of Example 1. However, a
  • FIGS. la-d TEM images of the resulting hydroxyapatite particles are shown in FIGS. la-d. These images show lattice fringes indicating crystallinity of the particles and also show relatively uniform particle size and morphology.
  • the XRD diffraction pattern is shown in FIG. 3b, which also confirms the presence of HAp particles.
  • Example 3 Room temperature crystallization of hydroxyapatite in a self buffering solution.
  • Calcium acetate hydrate and potassium orthophosphate hydrate solutions were prepared as described in Example 1.
  • the potassium orthophosphate hydrate solution was divided in half and acetic acid was added to one of the two portions until the pH of the solution was 7.4 (volume depends on total solution volume, for example 50OmL solution needs about 23mL of glacial acetic acid). Proportional amounts of each of the three solutions were then measured out to create a calcium to phosphate ratio of 1.67 and pH of 7.4 (final concentrations of ions if they were to remain in solution would be 0.5m/0.3m).
  • a 20 mL reaction required 1OmL of the calcium solution to be measured and poured into a beaker and 8.5mL of the phosphate solution (unadjusted) to be added to the calcium solution followed by 1.5mL of the pH adjusted solution. Agitation via stirring with a glass rod was then performed until the solution appeared completely mixed and white (a gelation is not seen). The slurry was not aged. The concentrate or solution was then dried in an oven at 7O 0 C for 24 hours and desiccated until use or immediately atomized onto a TEM grid for characterization. X-Ray diffraction confirmed the phase formed was hydroxyapatite with no detectable secondary phases or peaks present. An average density of 2.2 g/cm 3 was determined via Helium pycnometry.
  • FIGS. 2a-e TEM images of the resulting hydroxyapatite particles are shown in FIGS. 2a-e. These images show lattice fringes indicating crystallinity of the particles and also show relatively uniform particle size and morphology. Dispersed particles having a particle size less than IOnm are shown.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for preparing nanoscale hydroxyapatite particles by combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale hydroxyapatite particles and the amounts are combined under ambient conditions to produce the hydroxyapatite particles. Nanoscale hydroxyapatite particles are also presented.

Description

BIOMIMETIC HYDROXYAPATITE SYNTHESIS
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Serial No. 60/758,207, which was filed on January 12, 2006, the disclosure of which is incorporated herein by reference.
STATEMENTREGARDINGFEDERALLYSPONSOREDRESEARCH
The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grant DGE033196 awarded by the National Science Foundation.
BACKGROUND OF THE INVENTION
Hydroxyapatite (HAp, chemical formula Ca10(PO4)6(OH)2) has attracted the attention of researchers over the past thirty years as an implant material because of its excellent biocompatibility and bioactivity. HAp has been extensively used in medicine for implant fabrication. It is commonly the material of choice for the fabrication of dense and porous bioceramics. Its general uses include biocompatible phase-reinforcement in composites, coatings on metal implants and granular fill for direct incorporation into human tissue. It has also been extensively investigated for non-medical applications such as a packing material/support for column chromatography, gas sensors and catalysts, as a host material for lasers, and as a plant growth substrate.
Previously explored methods of hydroxyapatite synthesis for particles include plasma spraying, hydrothermal synthesis, freeze drying, sol-gel, phase transformation, mechanochemical synthesis, chemical precipitation, and precipitation in simulated body fluid (SBF). AU of these methods produce products witn varying levels oi purity, size, crystallinity, and yield. Plasma spraying, hydrothermal synthesis, sol-gel, phase transformation, mechanochemical synthesis, and chemical precipitation require elevated temperatures and/or extreme pH values in the fabrication of hydroxyapatite. These conditions can raise important questions among biologists when considering the material for in vivo applications because they are not biomimetic and, in most cases, do not yield biomimetic structures or morphologies. Furthermore, precipitation in simulated body fluid has such a low yield or long reaction time, it is not practical for use in manufacturing implants. Therefore, a need exists for hydroxyapatite synthesis to take place at room temperature and optional neutral pH to allow the exploration of synthesis with live cells, including those in living organisms.
SUMMARY OF THE INVENTION
There is provided, in accordance with the present invention, a method for preparing nanoscale hydroxyapatite particles by combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale hydroxyapatite particles and the amounts are combined under essentially ambient conditions to produce the hydroxyapatite particles. One embodiment includes a stable colloidal suspension of nanoscale hydroxyapatite particles suspended in a biocompatible ionic solution prepared by the method of the present invention, wherein the ionic solution includes physiological concentrations of phosphate and acetate anions and sodium or potassium cations.
Also provided are powdered hydroxyapatite particles having a BET surface area between about 200 and about 3000 m2/g and a particle size between about lnm and about 9nm.
In one embodiment, a stable colloidal suspension of the hydroxyapatite particles suspended in a biocompatible ionic solution is provided. Also provided is a kit for use in preparing nanoscaie nyαroxyapanxe pauuacs, wherein the kit includes (a) an amount of a calcium ion source, which includes calcium acetate, and (b) an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscaie hydroxyapatite particles when combined under ambient conditions. BRIEF DESCRIPTION OF THE DRAWINGS
FIGS, la-d are transmission electron microscopy (TEM) images of particles prepared according to the method of Example 2;
FIGS. 2a-b are TEM images of particles prepared according to the method of Example 3; FIG. 2c is a TEM image of particles prepared according to the method of
Example 3 at a higher magnification than the images of FIGS. 2a-b;
FIG. 2d is a TEM image of particles prepared according to the method of Example 3 showing a particle size distribution of +/- lOnm;
FIG. 2e is a high resolution transmission electron microscopy (HRTEM) image of particles prepared according to the method of Example 3 ;
FIG. 3a is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1;
FIG. 3b is an XRD spectrum corresponding to HAp particles prepared according to the method of Example 2; FIG. 3c is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1, wherein the reactant concentrations were halved; and
FIG. 3d is an XRD spectrum corresponding to HAp particles prepared according to a method of Example 1, wherein the particles were heat treated at 9000C for 2 hours. DETAILED DESCRIPTION OF THE INVENTION
The present invention is related to methods for preparing nanoscale HAp particles and the HAp particles prepared therewith. Kits for use in preparing the particles and colloids containing the particles are also presented. Hydroxyapatite has reported uses for biomedical, chromatographic, and piezoelectric applications and has been synthesized by various techniques. However, reaction conditions for the preparation of HAp such as high temperatures, high pressures and extreme pH values, as well as low yield, vigorous washing requirements, and long reaction times limit biological applications. The methods of the present invention permit the formation under mild reaction conditions of HAp under conditions suitable for the above uses, especially biological use.
The method involves combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale HAp particles and the amounts are combined under essentially ambient conditions to produce the HAp particles.
Suitable phosphate ion sources include, but are not limited to, one or more of potassium or sodium orthophosphate; orthophosphoric acid; Group I phosphates, preferably monobasic, dibasic, or tribasic potassium or sodium phosphate; magnesium phosphate; ammonium phosphate; and the like. Potassium or sodium orthophosphate is preferred. In addition to calcium acetate, the calcium ion source may include one or more of calcium hydroxide, calcium oxalate, calcium acetate, calcium nitrate, calcium phosphate, calcium carbonate, calcium fluoride, and calcium chloride. Calcium acetate alone is preferred.
The calcium ion source, the phosphate ion source, or both are in solution prior to combining the sources. Preferably, the solution contains one or more of water, buffer, solvent, simulated body fluid, or fortified cell medium with or without serum. Suitable buffers include, but are not limited to, N-(2-hydroxyethyl)-piperazine-N'-2- ethanesulfonic acid (HEPES), 2-(bis(2-hydroxyethyl)amino)-2-(hydroxymethyl)propane- 1,3-diol (BIS-TRIS), 3-(N-Morρholino)-propanesulfonic acid (MOPS), N-(2- Acetamido)-2-aminoethanesulfonic acid (ACES), N-(2-Acetamido)iminodiacetic Acid (ADA), N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic Acid (BES), 3-[N,N-bis(2- hydroxyethyl)amino]-2-hydroxypropanesulfonic acid (DIPSO), 4-(N- morpholino)butanesulfonic acid (MOBS), 3-[N-morpholino]-2-hydroxypropanesulfonic acid (MOPSO), piperazine- 1 ,4-bis(2-ethanesulfonic acid) (PIPES), 3-[N-
Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO), N- Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), and acetic acid. A preferred buffer is acetic acid.
If a particular ion source is not in solution, the source is in a solid phase. An optional step includes agitating the combination until HAp is formed.
Agitating the combination accelerates the formation of hydroxyapatite. As used herein, the term "agitate" refers to mechanical movement, for example, vibrating, vortexing, swirling, shaking, ultrasonicating, stirring, or the like that causes mixing. Mechanical movements include movements performed by hand. When the precursor composition is completely mixed, an extremely viscous gel is formed. This thixotropic material exhibits shear thinning after further intense agitation and returns to a milky solution. Optionally, this solution is allowed to age for a period between 2 minutes and 10 days. During the aging process, additional agitation may or may not be applied to continue mixing. The aging time allows Ostwald ripening of the particles, therefore, the particles aged longer exhibit a larger particle size.
Essentially ambient conditions are employed. A preferred temperature range is between -1O0C and 45°C. At room temperature, HAp particles are typically produced within 1 minute to an hour. Combining the sources while heating will speed up the rate of reaction to more quickly produce HAp, while combining the ion sources while cooling will decrease the rate at which HAp particles form.
During the course of the reaction, a pH swing may occur, which is varied with the calcium to phosphate stoichiometry. A preferred embodiment, in which the calcium to phosphate ratio is about 1.67, exhibits a pH swing of 12 down to 7 over the time of a 4 hour reaction. The pH of the gel phase is 12; just after the shear thinning and return to solution, the pH is 10; after 3 hours of reaction, the pH is 8; and after 4 hours of reaction, the pH returns to neutral. The time to neutral, however, also depends on the employment or omission of agitation throughout the reaction that may enhance kinetics and diffusion of the ions in the formation of hydroxyapatite.
The employment of a buffer as the reaction medium moderates the pH change, which affects the product formed. Hydroxyapatite is formed, but secondary phases of calcium phosphate and calcium carbonate may be additionally formed, but can be remedied through process variations, for example, bubbling with nitrogen, addition of chelating agents, or use of additional pH adjustments or buffers.
Another optional step includes adding one or more dopant ions suitable for substitution into the HAp lattice. Such ions are readily determinable by one of skill in the art. Suitable ions include, but are not limited to, magnesium, fluorine, chlorine, potassium, iron, carbonate, sodium, and the like. The HAp particles of the present invention can also be doped with ions of one or more rare earth elements.
Following the aging process, a washing step can be performed. This step includes, for example, filtration, centrifuging, and/or liquid replacement. Centrifuging or liquid replacement are preferred. Minimal washing cycles are needed because of the nontoxic nature of the ions left in solution. In one embodiment, the citrate wash disclosed in U.S. Patent No. 6,921,544, the contents of which are incorporated herein by reference in their entirety, is used to remove at least a portion of an amorphous phase if the amorphous phase is considered an undesired impurity.
To produce solid hydroxyapatite, the solution is dried. Suitable drying techniques are readily determinable by those of skill in the art. Preferred drying techniques include evaporative and sublimation-based drying methods, for example, oven drying and freeze drying. The methods according to the present invention can take place in any suitable reaction system. An exemplary system includes a flow reactor for continuous production of hydroxyapatite.
Powdered HAp particles produced according to the methods of the present invention are also presented. The HAp particles have a BET surface area between about 200 and about 3000 m2/g and a particle size between about 1 nm and about 9 nm. In one embodiment, the particles have a dispersed particle size between about 1 and about 9 nm. The term "dispersed" is defined herein in the context of colloidal chemistry where the particles maintain an inter-particle spacing such that no physical contact is made between the particles. The term "aggregated" is defined herein as adjacent particles having no inter-particle spacing and making contact with the nearest neighboring particles. In another embodiment, the particles are aggregated and have an aggregated particle size equal to or greater than about 2 nm, preferably between about 2nm and about 5 mm.
The composition of the powdered HAp particles is stoichiometric or non- stoichiometric with respect to calcium and phosphate. For example, the XRD diffraction pattern of FIG. 3d represents the results of a standard test for stoichiometry. FIG. 3d shows the presence of peaks corresponding to tricalcium phosphate (TCP) after the sample was heat treated at 9000C for 2 hours. The presence of TCP indicates a non- stoichiometric composition and/or an amorphous phase. In one embodiment, at least a portion of the composition includes an amorphous phase. In one embodiment, the ratio of calcium to phosphate in the HAp particles is between 1.25 and 2.5.
The HAp particles exhibit a spherical or non-spherical morphology. The term "spherical" is used herein to mean equiaxed particles having either a primary or secondary particle structure. Given that hydroxyapatite has no toxicity and its components are low cost, such a technology presents great promise for a range of applications.
HAp particles having the size distribution of the present invention are effective in drug delivery because they are more capable of penetrating the cellular wall and carry a much higher surface area for adsorption of drug molecules. The range also allows the particles to be used intravenously as a drug therapy or for transdermal drug delivery. The size range is also important in biomaterial applications because it is close to what is seen naturally in the body. Being smaller, it will also be more readily processable by cells and tissues for regeneration and resorption.
Devices based on hydroxyapatite are typically in the form of polycrystalline ceramics, polymer-ceramic composites, or films on a metallic surface such as titanium. The powders produced in this invention can be used in conventional processes to make all three forms of materials, using conventional methods such as solid state sintering for polycrystalline ceramics, polymer-melt processing for polymer-ceramic composites and plasma spraying for hydroxyapatite-coated titanium metal. The particles of this invention can be grown directly onto the metal surfaces without the need for any high temperature processing.
The hydroxy apatite of the present invention is also useful in the preparation of compounds for use as granular fill for direct incorporation into the hard tissues of humans or other animals, and as bone implantable materials. The present invention thus includes granular fill compounds, bone implant materials, tooth filling compounds, bone cements and dentifrices containing the hydroxyapatite of the present invention. The products are formulated and prepared by substituting the hydroxyapatite of the present invention for hydroxyapatite in conventional hydroxyapatite-based products. The compounds may be prepared from metallic and polymeric hydroxyapatite composites. Suitable polymers include polysaccharides, poly(alkylene oxides), polyarylates, for example those disclosed in U.S. Patent No. 5,216,115, block co-polymers of poly(alkylene oxides) with polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 5,658,995, polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 5,670,602, free acid polycarbonates and polyarylates, for example those disclosed in U.S. Patent No. 6,120,491, polyamide carbonates and polyester amides of hydroxy acids, for example those disclosed in U.S. Patent No. 6,284,862, polymers of L-tyrosine derived diphenol compounds, including polythiocarbonates and polyethers, for example those disclosed in U.S. Patent No. RE37,795, strictly alternating poly(alkylene oxide) ethers, for example those disclosed in U.S. Patent No. 6,602,497, polymers listed on the United States FDA "EAFUS" list, including polyacrylamide, polyacrylamide resin, modified poly(acrylic acid-co- hypophosphite), sodium salt polyacrylic acid, sodium salt poly(alkyl(C 16-22) acrylate), polydextrose, poly(divmylbenzene-co-ethylstyrene), poly(divinylbenzene-co- trimethyl(vinylbenzyl)ammonium chloride), polyethylene (m.w. 2,00-21,000), polyethylene glycol, polyethylene glycol (400) dioleate, polyethylene (oxidized), polyethyleneimine reaction product with 1,2-dichloroethane, polyglycerol esters of fatty acids, polyglyceryl phthalate ester of coconut oil fatty acids, polyisobutylene (min. m.w. 37,000), polylimonene, polymaleic acid, polymaleic acid, sodium salt, poly(maleic anhydride), sodium salt, polyoxyethylene dioleate, polyoxyethylene (600) dioleate, polyoxyethylene (600) mono-rici noleate, polyoxyethylene 40 monostearate, polypropylene glycol (m.w. 1,200-3,000), polysorbate 20, polysorbate 60, polysorbate 65, polysorbate 80, polystyrene, cross-linked, chloromethylated, then aminated with trimethylamine, dimethylamine, diethylenetriamine, or triethanolamine, polyvinyl acetate, polyvinyl alcohol, polyvinyl polypyrrolidone, and polyvinylpyrrolidone, and polymers listed in U.S. Patent No. 7,112,417, the disclosures of all of which are incorporated herein by reference in their entirety.
Also presented is a kit for use in preparing nanoscale HAp particles of the present invention. The kit includes (a) an amount of a calcium ion source comprising calcium acetate and (b) an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale HAp particles when combined under ambient conditions. The kit can be used to prepare HAp particles prior to the introduction of the particles into a patient. Alternatively, the kit can be used to combine components (a) and (b) in a patient in need thereof for the preparation, and subsequent deposit, of HAp particles in vivo. The two ion sources are provided in separate containers. Other components may be present depending upon the intended therapeutic use. Yet another aspect of the present invention includes a stable colloidal suspension with nanoscale HAp particles suspended in a biocompatible ionic solution prepared according to the methods of the present invention, wherein the ionic solution includes physiological concentrations of phosphate and acetate anions and sodium or potassium cations. Also presented is a stable colloidal suspension with the HAp particles of the present invention suspended in a biocompatible ionic solution.
A suitable ionic solution is readily determinable by one of skill in the art. In one embodiment, the ionic solution includes the mother liquor from which the hydroxyapatite particles were produced. The mother liquor can be formulated to produce an ionic buffer upon HAp formation. For example, the mother liquor could form a phosphate buffered saline (PBS) solution upon formation of HAp. In another embodiment, the ionic solution includes a solution prepared independently of the hydroxyapatite particles, for example, one of the aforementioned buffers.
The following non-limiting examples set forth herein below illustrate certain aspects of the invention. EXAMPLES
Example 1 - Room temperature crystallization of hydroxyapatite in water.
Calcium acetate hydrate (99% Acros Organics, Belgium, CAS # 114460-21-8) and potassium orthophosphate hydrate (Acros Organics, Belgium, CAS# 27176-10-9) were used as reactants for the synthesis of hydroxyapatite. First, a 1.0 molal calcium acetate hydrate solution was made using distilled, deionized water. Then, a 0.6 molal solution of potassium orthophosphate hydrate was made using distilled, deionized water. Equal volumes of each were then measured out for the reaction to create a calcium to phosphate ratio of 1.67 (final concentrations of ions if they were to remain in solution would be 0.5m/0.3m). A 100 mL reaction required 5OmL of the calcium solution to be measured and poured into a beaker and 5OmL of the phosphate solution to be added. Agitation via vortexing was then performed until and through the gelation stage. Once the gel returned to solution, the slurry was then allowed to age for 2 minutes. The concentrate was then dried in an oven at 7O0C for 24 hours and desiccated until use or immediately atomized onto a Transmission Electron Microscopy (TEM) grid for characterization.
X-Ray diffraction (XRD) confirmed the phase formed was hydroxyapatite with no detectable secondary phases or peaks present. FIG. 3a is an XRD diffraction pattern corresponding the HAp particles prepared according to this method, which were washed followed by drying in a 7O0C oven. The broadness of the peaks in FIG. 3a indicates nanoscale particles. Furthermore, the peaks match the standard reference peaks for hydroxyapatite. Helium pycnometry confirms an average particulate density of 2.4 g/cm3. FIG. 3c is an XRD diffraction pattern corresponding to HAp particles prepared according to this method, wherein the reactant concentrations were halved. FIG. 3c also confirms the presence of HAp particles.
Example 2 - Room temperature crystallization of hydroxyapatite in water. Hydroxyapatite was prepared according to the method of Example 1. However, a
2.0 molal calcium acetate hydrate solution and a 1.2 molal solution of potassium orthophosphate hydrate were used. The final concentrations of ions if they were to remain in solution after mixing would be 1.0m/0.6m.
TEM images of the resulting hydroxyapatite particles are shown in FIGS. la-d. These images show lattice fringes indicating crystallinity of the particles and also show relatively uniform particle size and morphology.
The XRD diffraction pattern is shown in FIG. 3b, which also confirms the presence of HAp particles.
Example 3 - Room temperature crystallization of hydroxyapatite in a self buffering solution.
Calcium acetate hydrate and potassium orthophosphate hydrate solutions were prepared as described in Example 1. The potassium orthophosphate hydrate solution was divided in half and acetic acid was added to one of the two portions until the pH of the solution was 7.4 (volume depends on total solution volume, for example 50OmL solution needs about 23mL of glacial acetic acid). Proportional amounts of each of the three solutions were then measured out to create a calcium to phosphate ratio of 1.67 and pH of 7.4 (final concentrations of ions if they were to remain in solution would be 0.5m/0.3m). A 20 mL reaction required 1OmL of the calcium solution to be measured and poured into a beaker and 8.5mL of the phosphate solution (unadjusted) to be added to the calcium solution followed by 1.5mL of the pH adjusted solution. Agitation via stirring with a glass rod was then performed until the solution appeared completely mixed and white (a gelation is not seen). The slurry was not aged. The concentrate or solution was then dried in an oven at 7O0C for 24 hours and desiccated until use or immediately atomized onto a TEM grid for characterization. X-Ray diffraction confirmed the phase formed was hydroxyapatite with no detectable secondary phases or peaks present. An average density of 2.2 g/cm3 was determined via Helium pycnometry.
TEM images of the resulting hydroxyapatite particles are shown in FIGS. 2a-e. These images show lattice fringes indicating crystallinity of the particles and also show relatively uniform particle size and morphology. Dispersed particles having a particle size less than IOnm are shown.
The foregoing examples and description of the preferred embodiments should be taken as illustrating, rather than as limiting the present invention as defined by the claims. As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not regarded as a departure from the spirit and script of the invention, and all such variations are intended to be included within the scope of the following claims.

Claims

What is claimed is:
1. A method for preparing nanoscale hydroxyapatite particles comprising combining an amount of a calcium ion source comprising calcium acetate and an amount of a phosphate ion source, wherein said amounts are sufficient to produce nanoscale hydroxyapatite particles and said amounts are combined under essentially ambient conditions to produce said hydroxyapatite particles.
2. The method of claim 1, wherein said phosphate ion source is selected from the group consisting of potassium orthophosphate, sodium orthophosphate, orthophosphoric acid, Group I phosphates, magnesium phosphate, ammonium phosphate, and a combination of two or more thereof.
3. The method of claim 2, wherein said Group I phosphates are selected from the group consisting of monobasic sodium phosphate, dibasic sodium phosphate, tribasic sodium phosphate, monobasic potassium phosphate, dibasic potassium phosphate, and tribasic potassium phosphate.
4. The method of claim 1 , wherein said calcium ion source further comprises calcium hydroxide, calcium oxalate, calcium nitrate, calcium phosphate, calcium carbonate, calcium fluoride, calcium chloride, or a combination of two or more thereof.
5. The method of claim 1 further comprising agitating the combination until hydroxyapatite is formed.
6. The method of claim 1 , wherein said ion sources are combined at a temperature between -1O0C and 450C.
7. The method of claim 6, wherein said ion sources are combined with cooling.
8. The method of claim 6, wherein said ion sources are combined with heating.
9. The method of claim 1, further comprising adding a buffer solution to the combination.
10. Powdered hydroxyapatite particles comprising a BET surface area between about 200 and about 3000 m2/g and a particle size between about lnm and about 9nm.
11. The powdered hydroxyapatite of claim 10 consisting essentially of particles having a dispersed particle size between about lnm and about 9nm.
12. The powdered hydroxyapatite of claim 10 consisting essentially of particles having an aggregated particle size between about 2nm and about 5mm.
13. The powdered hydroxyapatite of claim 10, wherein the ion ratio of calcium to phosphate of said particles is stoichiometric.
14. The powdered hydroxyapatite of claim 10, further comprising an amorphous phase.
15. The powdered hydroxyapatite of claim 10, wherein the ion ratio of calcium to phosphate is between 1.25 and 2.5.
,
16. The powdered hydroxyapatite of claim 10, wherein said particles are doped with one or more ions suitable for substitution into the HAp lattice.
17. A kit for use in preparing nanoscale hydroxyapatite particles, said kit comprising (a) an amount of a calcium ion source comprising calcium acetate and (b) an amount of a phosphate ion source, wherein said amounts are sufficient to produce nanoscale hydroxyapatite particles when combined under ambient conditions.
18. The kit of claim 17, wherein said phosphate ion source is selected from the group consisting of potassium orthophosphate, sodium orthophosphate, orthophosphoric acid, Group I phosphates, magnesium phosphate, ammonium phosphate, and a combination of two or more thereof.
19. The kit of claim 17, wherein said Group I phosphates are selected from the group consisting of monobasic sodium phosphate, dibasic sodium phosphate, tribasic sodium phosphate, monobasic potassium phosphate, dibasic potassium phosphate, and tribasic potassium phosphate.
20. The kit of claim 17, wherein said calcium ion source further comprises calcium hydroxide, calcium oxalate, calcium nitrate, calcium phosphate, calcium carbonate, calcium fluoride, calcium chloride, or a combination thereof.
21. The kit of claim 17, further comprising a buffer solution.
22. A stable colloidal suspension comprising nanoscale hydroxyapatite particles suspended in a biocompatible ionic solution prepared by the method of claim 1, wherein said ionic solution comprises physiological concentrations of phosphate and acetate anions and sodium or potassium cations.
23. The suspension of claim 22, wherein said ionic solution is formed from the mother liquor from which said hydroxyapatite particles were produced.
24. The suspension of claim 22, wherein said ionic solution comprises a solution prepared independently of the hydroxyapatite particles.
25. A stable colloidal suspension comprising the hydroxyapatite particles of claim 10 suspended in a biocompatible ionic solution.
26. The suspension of claim 25, wherein said ionic solution is formed from the mother liquor from which said hydroxyapatite particles were produced.
27. The suspension of claim 25, wherein said ionic solution comprises a solution prepared independently of the hydroxyapatite particles.
EP07718197A 2006-01-12 2007-01-12 Biomimetic hydroxyapatite synthesis Withdrawn EP1981514A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75820706P 2006-01-12 2006-01-12
PCT/US2007/060505 WO2007084858A2 (en) 2006-01-12 2007-01-12 Biomimetic hydroxyapatite synthesis

Publications (1)

Publication Number Publication Date
EP1981514A2 true EP1981514A2 (en) 2008-10-22

Family

ID=38288352

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07718197A Withdrawn EP1981514A2 (en) 2006-01-12 2007-01-12 Biomimetic hydroxyapatite synthesis

Country Status (3)

Country Link
EP (1) EP1981514A2 (en)
AU (1) AU2007205961B2 (en)
WO (1) WO2007084858A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9776869B2 (en) 2015-09-25 2017-10-03 Clean World Technologies Ltd. Producing calcium phosphate compositions

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8287914B2 (en) * 2006-01-12 2012-10-16 Rutgers, The State University Of New Jersey Biomimetic hydroxyapatite synthesis
PL210026B1 (en) * 2009-03-17 2011-11-30 Akademia Górniczo Hutnicza Im Stanisława Staszica Method of manufacturing the high-porous, bioactive calcium phosphate implant material
EP2574171A1 (en) * 2010-04-07 2013-04-03 Eman Ismail Abd El-Gawad Repair of fragmented dna and treatment of heavy metal intoxication by intravenous injection of nano-hydroxyapatite
CN106824236A (en) * 2017-02-21 2017-06-13 西华师范大学 Caesium or the hydroxyapatite catalyst of calcic of potassium doping and its preparation method and application
CN110775953B (en) * 2019-11-27 2023-03-31 中山市科信生物技术有限公司 Method for synthesizing thermodynamically stable hydroxyapatite with microscopic kinetic reaction limitation
CN112875665B (en) * 2021-02-07 2022-11-01 吉林大学 Hydroxyapatite microspheres for injection filling preparation and preparation method thereof
CN113797395B (en) * 2021-09-17 2023-02-21 北京爱康宜诚医疗器材有限公司 Nano hydroxyapatite/block copolymer composite material and preparation method thereof
CN115557480A (en) * 2022-10-28 2023-01-03 南京市儿童医院 A kind of synthetic method of cobalt-doped hydroxyapatite microsphere
CN116832223B (en) * 2023-07-27 2024-01-30 重庆生物智能制造研究院 A kind of medical absorbable calcium phosphate salt/polyester composite material and preparation method
CN120078922B (en) * 2025-03-14 2026-03-27 上海交通大学医学院附属瑞金医院 Chiral hierarchical hydroxyapatite nanosheets/bacterial cellulose membranes, their preparation, and their application in dressings for elderly skin wounds.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013591A (en) * 1997-01-16 2000-01-11 Massachusetts Institute Of Technology Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production
US6387414B1 (en) * 1999-08-05 2002-05-14 Nof Corporation Method for preparing hydroxyapatite composite and biocompatible material
US6921544B2 (en) * 2001-03-06 2005-07-26 Rutgers, The State University Magnesium-substituted hydroxyapatites
SE527610C2 (en) * 2004-06-15 2006-04-25 Promimic Ab Process for the preparation of synthetic crystalline calcium phosphate in nano size
EP1909859B1 (en) * 2005-07-21 2017-09-06 aap Biomaterials GmbH Method for producing hydroxyapatite particles, in particular subnanodisperse hydroxyapatite particles in a matrix

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007084858A3 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9776869B2 (en) 2015-09-25 2017-10-03 Clean World Technologies Ltd. Producing calcium phosphate compositions
US9776870B2 (en) 2015-09-25 2017-10-03 Clean World Technologies Ltd. Producing calcium phosphate compositions

Also Published As

Publication number Publication date
AU2007205961B2 (en) 2013-03-14
WO2007084858A3 (en) 2007-11-29
AU2007205961A1 (en) 2007-07-26
WO2007084858A2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
US8287914B2 (en) Biomimetic hydroxyapatite synthesis
AU2007205961B2 (en) Biomimetic hydroxyapatite synthesis
Munir et al. Synthesis, characterization, functionalization and bio-applications of hydroxyapatite nanomaterials: an overview
US8337904B2 (en) Magnesium-substituted hydroxyapatites
Shepherd et al. Substituted hydroxyapatites for bone repair
Uskoković et al. Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. I. Preparation and drug release
US9205035B2 (en) Ion substituted calcium phosphate particles
Vallet-Regí et al. Nanoceramics in clinical use: from materials to applications
CN1250449C (en) Rod-like apatite crystals, dispersions comprising them and preparation and use of said crystals and dispersions
WO2009088519A1 (en) Biomimetic hydroxyapatite composite materials and methods for the preparation thereof
Díaz-Cuenca et al. Biocompatible calcium phosphate-based ceramics and composites
El-Fiqi et al. Highly bioactive bone cement microspheres based on α-tricalcium phosphate microparticles/mesoporous bioactive glass nanoparticles: Formulation, physico-chemical characterization and in vivo bone regeneration
Song et al. Mineralization pathways of amorphous calcium phosphate in the presence of fluoride
EP2185133B1 (en) Calcium phosphate microspheres drug delivery system and process for preparing the same
Xia et al. Synthesis and release of trace elements from hollow and porous hydroxyapatite spheres
ES2906408T3 (en) Stabilized amorphous calcium phosphate doped with fluoride ions and a process for producing the same
Nassar et al. Biomaterials and sol-gel process: a methodology for the preparation of functional materials
Quadros et al. Implications of synthesis methodology on physicochemical and biological properties of hydroxyapatite
JP2019210186A (en) Phosphate sustained-release by silicon-based hollow particle including phosphate compound
WO2024134524A1 (en) Composite material based on bioactive glass and amorphous calcium phosphate, and the process for producing the same
Jiang Application of Calcium Phosphate based gels for encapsulation of therapeutic molecules
RS20220531A1 (en) NANOPARTICLE MESOPOROUS BIOACTIVE GLASS DOPED WITH STRONTIUM AND MAGNESIUM IONS
BR102018006848A2 (en) production process, composition and use of bioactive glass added with niobium

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080808

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 33/42 20060101ALI20081118BHEP

Ipc: A61K 38/39 20060101ALI20081118BHEP

Ipc: A61K 38/18 20060101AFI20081118BHEP

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140801